Frontiers in Medicine
June 12, 2026
Xiaofan Yang, Jing Qin, Wenqing Xu
Introduction This study aims to systematically evaluate, through a systematic review and meta-analysis, the effect of esketamine on postoperative negative emotions (anxiety and depression) and cognitive function in patients undergoing general anesthesia. Methods Following PRISMA guidelines, we systematically searched PubMed, Web of Science, Embase, Cochrane Library, and CNKI to identify studies...
Perioperative medicine (London, England)
June 12, 2026
Bowen Zhang, Zhun Wang, Kaili Yu et al.
Pancreaticoduodenectomy (PD) can lead to major trauma in terms of patients' mental health, including severe postoperative depression. This study aimed to investigate the effects of supplementing patient-controlled analgesia with low-dose esketamine on postoperative depression among patients undergoing PD. Eighty patients who were scheduled for PD were randomly assigned to either the control or...
Mental Health Weekly
June 12, 2026
Valerie A. Canady
For many patients with major depressive disorder, reaching remission — not just partial response — can significantly alter the course of illness, lowering the risk of relapse and improving day‐to‐day functioning. Yet that goal remains elusive for those with treatment‐resistant depression (TRD), where repeated medication failures, comorbid conditions, and lingering symptoms complicate care. Data...
Clinics and practice
June 12, 2026
Ana María De Granda-Beltrán, Alejandro Porras-Segovia, Daniel Núñez-arias et al.
Background: Treatment-resistant depression (TRD) poses a major clinical challenge, particularly when accompanied by suicidal behavior. Intranasal esketamine has demonstrated rapid antidepressant effects in TRD, but real-world comparative evidence remains limited. Methods: We conducted a six-month naturalistic prospective cohort study in two Spanish mental health centers, including 62 TRD...
Journal of Psychiatric Research
June 12, 2026
Juliana Lima Constantino, Tobias Stephan Freimann, Jens H van Dalfsen et al.
Oral esketamine is a potentially effective and well-tolerated treatment for treatment-resistant depression (TRD). However, around 50% of TRD individuals treated with oral esketamine do not achieve response, and this variation in response may be accounted for by interindividual differences between patients. Efforts to develop effective and personalized depression treatment strategies are...
European Psychiatry
June 10, 2026
Riccardo Guglielmo, Miriam Olivola, Alberto Inuggi et al.
Esketamine has demonstrated efficacy in treatment-resistant depression (TRD), but medium-term real-world functional outcomes remain understudied. This study described 6-month depressive symptoms and functional trajectories during routine esketamine treatment, focusing on functional outcomes and remission correlates. In this prospective multicenter study, 60 patients with TRD initiating...
Fortschritte der Neurologie · Psychiatrie
June 8, 2026
Udo Bonnet, Norbert Scherbaum, Georg Juckel et al.
Introduction: Esketamine nasal spray (EN) has been approved in Germany since 2021 for the treatment of treatment-resistant depression (TRD). Historically, the development of EN resulted from the positive results of randomized clinical trials on the off-label use of subnarcotic ketamine infusions (SKI) for TRD. How effective, tolerable, and safe is off-label SKI compared to EN? Methods: Narrativ...
Journal of Affective Disorders
June 8, 2026
Dian‐jeng Li, Tien-Wei Hsu, Te-Chang Changchien et al.
Little is known about esketamine's effectiveness for patients with major depressive disorder (MDD) comorbid substance use disorders (SUD). We conducted a retrospective cohort study using the TriNetX US Collaborative Network, including adults aged ≥18 years with MDD. Three propensity-score-matched (1:1) cohorts were defined based on treatment: esketamine, antidepressant-only, and repetitive...
Journal of Affective Disorders
June 7, 2026
Lindsay L Benster, Jordan N Kohn, Benjamin Wade et al.
Repetitive transcranial magnetic stimulation (rTMS) and intranasal esketamine are FDA-approved for treatment-resistant depression (TRD), yet comparative real-world data on response trajectories and predictors of outcomes remain limited. A retrospective analysis was performed using electronic medical records from UC San Diego Health. Adults with TRD treated with rTMS (n = 279) or intranasal...
European Psychiatry
June 1, 2026
P.-M. Llorca, Ludovic Samalin, Emilie Olié et al.
Introduction: Esketamine nasal spray (ESK) was approved in 2019 in Europe for adults with Treatment-Resistant Depression (TRD), defined as inadequate response to at least two different antidepressants during the current moderate to severe depressive episode Objectives: To assess patient-reported outcomes related to symptomatology, quality of life, and occupational impairment over 12 months...